Cite
Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
MLA
Zeng, Yanbin, et al. “Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.” Journal of Clinical Pharmacology, vol. 63, no. 8, Aug. 2023, pp. 909–17. EBSCOhost, https://doi.org/10.1002/jcph.2244.
APA
Zeng, Y., Guo, X., Xiao, F., & Zhang, H. (2023). Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Journal of Clinical Pharmacology, 63(8), 909–917. https://doi.org/10.1002/jcph.2244
Chicago
Zeng, Yanbin, Xiaohui Guo, Fengjiao Xiao, and Haixia Zhang. 2023. “Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.” Journal of Clinical Pharmacology 63 (8): 909–17. doi:10.1002/jcph.2244.